Diana Frances Clarke, Pharm.D.

Assistant Professor, Pediatrics

Diana Clarke
617.638.5300
72 E. Concord St Instructional (L)

Biography

Diana Clarke, Pharm.D., is an Assistant Professor of Pediatrics in Infectious Diseases at the Boston University School of Medicine and Pediatric HIV Pharmacotherapy Specialist at Boston Medical Center. She works in the Pediatric ID clinic and the High-Risk OB clinic where she is actively involved in the management of children and pregnant women living with HIV. Her commitment to pediatrics is demonstrated through her memberships to the WHO Pediatric Antiretroviral Working Group and as a Consultant, Human Resources and Services Administration, HIV/AIDS Bureau (HRSA) for the DHHS Pediatric and Perinatal HIV Guidelines Committees. Her research interests include neonatal pharmacokinetics of antiretroviral agents and pharmacokinetics of anti-infectives in pregnant women. She is currently Chair of several IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Network, NIH) protocols and a member of the IMPAACT Scientific Treatment Committee.

Education

  • State University of New York at Buffalo, PharmD
  • University of Rhode Island College of Pharmacy, BS

Publications

  • Published on 10/6/2021

    Piscitelli J, Nikanjam M, Best BM, Acosta E, Mirochnick M, Clarke DF, Capparelli EV, Momper JD. Optimizing Dolutegravir Initiation in Neonates using Population Pharmacokinetic Modeling and Simulation. J Acquir Immune Defic Syndr. 2021 Oct 06. PMID: 34629412.

    Read at: PubMed
  • Published on 3/26/2021

    Epstein RL, Penwill N, Clarke DF, Hamilton S, Horbowicz K, Dorfman D, Moses JM, Cooper ER. "Meds-in-Hand" Intervention to Reduce Critical Process Delays in Pediatric Human Immunodeficiency Virus Post-Exposure Prophylaxis. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):196-200. PMID: 32347312.

    Read at: PubMed
  • Published on 12/15/2020

    Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, Chain A, Smith E, Teppler H, Hazra R, Calabrese K, Graham B, Popson S, Bryson Y, Mirochnick M. Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):626-634. PMID: 32925360.

    Read at: PubMed
  • Published on 5/1/2020

    Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020 05 01; 84(1):70-77. PMID: 31913995.

    Read at: PubMed
  • Published on 12/1/2019

    Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. J Acquir Immune Defic Syndr. 2019 12 01; 82(4):392-398. PMID: 31658182.

    Read at: PubMed
  • Published on 9/1/2018

    Schreiner CN, Ahlfors CE, Wong RJ, Stevenson DK, Clarke DF, Mirochnick M. In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding. Pediatr Infect Dis J. 2018 09; 37(9):908-909. PMID: 29561509.

    Read at: PubMed
  • Published on 11/8/2017

    Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol. 2018 Jan; 11(1):83-93. PMID: 29039686.

    Read at: PubMed
  • Published on 1/1/2017

    Clarke DF, Yildirim I, Cooper ER. Rapid Initiation of Antiretrovirals in Two Newly Diagnosed HIV-infected Infants. Pediatr Infect Dis J. 2017 Jan; 36(1):61-62. PMID: 27749654.

    Read at: PubMed
  • Published on 11/1/2014

    Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr. 2014 Nov 1; 67(3):310-5. PMID: 25162819.

    Read at: PubMed
  • Published on 9/1/2013

    Clarke DF, Wong RJ, Wenning L, Stevenson DK, Mirochnick M. Raltegravir in vitro effect on bilirubin binding. Pediatr Infect Dis J. 2013 Sep; 32(9):978-80. PMID: 23470680.

    Read at: PubMed

View 5 more publications: View full profile at BUMC

View all profiles